Blood cell growth factor

Smith TJ, et al. 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors An Evidence-Based Clinical Practice Guideline, www.asco.org accessed May 17, 2006. 

Risser J, Du XL. Use of white blood cell growth factors and risk of acute myeloid leukemia or myelodysplastic syndrome among elderly patients with non-Hodgkin lymphoma. Cancer 2010 116(22) ... 

Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al. 2006 update of recommendations for the use of white blood cell growth factors an evidence-based clinical practice guideline. J CUn Oncol 2006 24(19) 3187-205. 

F4. Ford, R., Tamayo, A., Martin, B., Niu, K., Claypool, K., Cabanillas, F., and Ambrus, J., Jr., Identification of B-cell growth factors (interleukin-14 high molecular weight-B-cell growth factors) in effusion fluids from patients with aggressive B-cell lymphomas. Blood 1, 283—293... 

Cell growth factors may also be produced by a distant cell or tissue and travel to the responding cell via the blood stream (an endocrine response as shown by insulin). These factors are classically known as hormones. Although endocrine factors are present in serum, conditioned medium is frequently a better source of autocrine and paracrine factors. 

Neupogen Colony-stimulating factor White blood cell growth 1056... 

Bone marrow suppression is the single most important dose-limiting factor with cytotoxic agents. Repeated blood monitoring is essential and transfusion of any/all formed elements of the blood may be needed, e.g. platelet transfusion for thrombocytopenic bleeding or where the platelet count falls below 10 x 10 /1. Cell growth factors. 

Emura, M., Nagai, S., Takouchi, M., Kitaichi, M. and Izumi, T. (1990). In vitro production of B-cell growth factor and B-cell differentiation factor by peripheral blood mononuclear cells and bronchoalveolar lavage T lymphocytes from patients with idiopathic pulmonary fibrosis. Clin. Exp. Immunol. 82, 133-139. 

Srdan V, Kantarjian H, Manshouri T, et al. Prognostic significance of cellular vascular endothelial cell growth factor expression in chronic phase chronic myelogenous leukemia. Blood 2002 99 2265-2267. 

Human leukocyte antigen CD45 Dako-LCA Five or more high molecular weight glycoproteins on the surface of most human leukocytes Human peripheral blood lymphocytes maintained in T-cell growth factor Ventana NA HIER... 

One recent area of intense research interest is the effects of various thymic factors on the production of soluble mediators (lymphokines) by T cells, most notably T cell growth factor [TCGF or interleukin-2 (IL-2)] and 7 interferon (IFN-7). Interleukin-2 is released by activated T cells and plays a pivotal role in sustaining both proliferative and cytotoxic immune responses. Interferon, on the other hand, augments T cell cytotoxic activity but exhibits antiproliferative effects. It has been demonstrated that Toj can increase IFN-7 production in vitro in human peripheral blood lymphocytes (Svedersky et al., 1982), whereas TF5, but not Taj, has a pronounced effect on increasing IL-2 production (Zatz et al., 1984a). Similar effects have been demonstrated with thymulin in animals (Palacios, 1983). Thus, it is possible that the variable effects of thymic hormones observed to date in human fiinctional assays may be related to differences in their ability to influence lymphokine production. 

Elcin, Y. M., Dixit, V., and Gitnick, G. (1996). Controlled release of endothelial cell growth factor from Chitosan-albumin microspheres for localized angiogenesis In vitro and in vivo studies, Artif. Cells Blood Substit. Immobil. BiotechnoL, 24,257-271. 

Ko, C., V. Dixit, W. Shaw and G. Gitnick, in vitro slow release profile of endothelial cell growth factor immobilized within calcium alginate microbeads. Art. Cells, Blood Subs., andimmob. Biotech., 23 (1995) 143-151. 

The term hematopoietic stem cell transplantation has supplanted the previously employed term bone marrow transplantation to reflect the broader range of donor stem cell sources that are now available bone marrow, fetal cord blood, and growth-factor-stimulated peripheral blood (Kotloff et al. 2004). Hematopoietic stem cell (HSC) transplantation is being used with increasing frequency for the treatment of leukemia, aplastic anemia, myeloma, and some forms of lymphoma and solid tumors. It is estimated that more than 50,000 marrow and HSC transplantations are performed annually worldwide (Tabbara et al. 2002). 

---